Moderna (MRNA) stock is climbing 8% after the drug maker won a key court case and its CEO bought shares on the open market. MRNA's Court Victory A German court ruled that BioNTech (BNTX) and ...

Moderna Inc.’s stock tumbled 4% Thursday after a report that health officials are reviewing a contract the company won from the Biden administration to support efforts to develop a bird-flu ...

Shares of Moderna have been volatile at the start of 2025 amid a weak growth outlook. Demand for its COVID-19 vaccine has dropped while sales of its new RSV vaccine have been sluggish. An ...

In a statement, the court in the city of Duesseldorf said that Pfizer and BioNTech would have to provide information on earnings derived from the use of the patent and that they owe Moderna ...

Pam Danziger reports on retail, focused on the luxury consumer market. It’s been a year since Jennifer Sey and her XX-XY Athletics brand entered the large and fiercely competitive athletic ...

Just a few years since pioneering a Covid-19 vaccine, Moderna faces a hostile political environment and a looming patent problem. We recently compiled a list of the 12 Most Promising Biotech ...

The trial compared Moderna's MRNA-4157/V940 vaccine given alongside Merck & Co's cancer immunotherapy Keytruda (pembrolizumab) to Keytruda alone in patients with the skin cancer melanoma.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...